CORDIS
EU research results

CORDIS

English EN
Systems biology towards novel chronic kidney disease diagnosis and treatment

Systems biology towards novel chronic kidney disease diagnosis and treatment

Objective

Chronic kidney disease (CKD) affects up to 10% of the population. Besides eventual progression towards end stage renal disease CKD impacts the patient’s quality of life by causing serious comorbidities including cardiovascular complications and bone metabolism disorders. On the everyday clinical level early stage diagnosis and tailored treatment of CKD are still inadequate. In addition, CKD seems not to have reached its appropriate emplacement in an epidemiological and healthcare perspective yet, and the pathophysiology of the disease on a molecular and cellular level is not well enough understood. Our sysKID consortium was installed for precisely addressing these issues: To unravel the molecular and cellular mechanisms of chronic kidney disease development, combine this information with clinical risk factors, and on this basis delineate chronic kidney disease biomarkers. These markers will allow us to perform preclinical studies of novel therapy approaches for halting disease progression, and will provide us with the materials for development and clinical evaluation of tools for early stage diagnosis as well as prognosis and treatment monitoring. sysKID assures a successful implementation of these goals by a truly international consortium of 27 leading research groups. We combine clinical know how, provide access to a huge chronic kidney disease sample and clinical data pool, and build a Systems Biology framework for chronic kidney disease by integrating molecular and cellular biology, computational biology, statistics and epidemiology. Our expert group is further complemented by a high level advisory board covering science, product development, and the patient’s perspective. sysKID implementation is structured for completing pre-clinical Proof of Concept studies of novel chronic kidney disease therapy regimes, and further for completing clinical evaluation of an epidemiological screening tool as well as of early stage chronic kidney disease diagnostic kits.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

EMERGENTEC BIODEVELOPMENT GMBH

Address

Gersthofer Strasse 29-31
1180 Vienna

Austria

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 816 380

Administrative Contact

Bernd Mayer (Dr.)

Participants (28)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITE VICTOR SEGALEN BORDEAUX II

France

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 965 360

MEDIZINISCHE UNIVERSITAT INNSBRUCK

Austria

EU Contribution

€ 1 526 360

MOSAIQUES DIAGNOSTICS GMBH

Germany

EU Contribution

€ 662 140

ProScience Communications - die Agentur fur Wissenschaftskommunikation GmbH

Germany

EU Contribution

€ 114 000

Steno Diabetes Center A/S

Denmark

EU Contribution

€ 336 672

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 336 160

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 620 120

SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH

Poland

EU Contribution

€ 166 240

SEMMELWEIS EGYETEM

Hungary

EU Contribution

€ 166 240

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 166 240

BIOCRATES LIFE SCIENCES AG

Austria

EU Contribution

€ 288 120

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 924 920

Biogazelle

Belgium

EU Contribution

€ 417 060

CELERA CORPORATION

United States

EU Contribution

€ 258 000

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Netherlands

EU Contribution

€ 385 160

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

EU Contribution

€ 186 614

UNIVERSITE DE BORDEAUX

France

EU Contribution

€ 261 160

WEIZMANN INSTITUTE OF SCIENCE

Israel

EU Contribution

€ 506 716

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 485 500

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

Italy

EU Contribution

€ 457 160

UNIVERSITAT DES SAARLANDES

Germany

EU Contribution

€ 455 720

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

Spain

AMGEN (EUROPE) GMBH

Switzerland

EU Contribution

€ 31 200

THE ANTIBODY LAB GMBH

Austria

EU Contribution

€ 446 800

UNIVERSIDAD DE CORDOBA

Spain

EU Contribution

€ 226 800

INSTITUT CATALA DE LA SALUT

Spain

EU Contribution

€ 457 052

UNIVERSITAETSKLINIKUM AACHEN

Germany

EU Contribution

€ 125 640

Project information

Grant agreement ID: 241544

Status

Closed project

  • Start date

    1 January 2010

  • End date

    31 December 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 15 743 594

  • EU contribution

    € 11 789 534

Coordinated by:

EMERGENTEC BIODEVELOPMENT GMBH

Austria

This project is featured in...